Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

X4 Pharmaceuticals (XFOR) EBITDA Margin (2018 - 2025)

Historic EBITDA Margin for X4 Pharmaceuticals (XFOR) over the last 6 years, with Q3 2025 value amounting to 1558.58%.

  • X4 Pharmaceuticals' EBITDA Margin rose 46021300.0% to 1558.58% in Q3 2025 from the same period last year, while for Sep 2025 it was 290.69%, marking a year-over-year increase of 20143000.0%. This contributed to the annual value of 1440.5% for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, X4 Pharmaceuticals' EBITDA Margin is 1558.58%, which was up 46021300.0% from 1329.55% recorded in Q2 2025.
  • In the past 5 years, X4 Pharmaceuticals' EBITDA Margin registered a high of 12629.31% during Q2 2024, and its lowest value of 6160.71% during Q3 2024.
  • In the last 4 years, X4 Pharmaceuticals' EBITDA Margin had a median value of 1979.76% in 2022 and averaged 1141.61%.
  • Examining YoY changes over the last 5 years, X4 Pharmaceuticals' EBITDA Margin showed a top increase of 46021300bps in 2025 and a maximum decrease of -139588600bps in 2025.
  • Over the past 4 years, X4 Pharmaceuticals' EBITDA Margin (Quarter) stood at 2235.75% in 2022, then increased by 18bps to 2642.38% in 2023, then tumbled by -192bps to 2418.08% in 2024, then surged by 36bps to 1558.58% in 2025.
  • Its EBITDA Margin stands at 1558.58% for Q3 2025, versus 1329.55% for Q2 2025 and 32.78% for Q1 2025.